Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic Research
In our coverage of the inaugural meeting of the MEP Action Group for the Medical Use of Psychedelics, we discussed the challenging experience faced by a psilocybin trial participant after the support provided by the study's protocol came to an end.
On the very same day that the participant's testimony was delivered in Brussels, Eddie Jacobs et al. published an article in Neuroethics titled, When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research (2023).
We asked Jacobs, a DPhil student working within the University of Oxford’s NEUROSEC team as well as the Wellcome Centre for Ethics and Humanities, a few questions about post-clinical-trial support.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks